Progress in the pharmacotherapy of uveitis: the art of personalized care.
Shivam H PatelAditya BelamkarAmir R HajrasoulihaDenis JusufbegovicThomas A CiullaPublished in: Expert opinion on pharmacotherapy (2022)
Initially, the treatment of noninfectious uveitis was limited to corticosteroids, which have a broad range of adverse ocular and systemic effects. Now new delivery and therapeutic options, such as biological response modulators, represent novel yet exciting additions to this armory and have the potential to alter the course of treatment as well as prognostic outcomes for uveitis patients. Further research is needed to evaluate the efficacy of this novel class of immunomodulators in uveitis therapy.
Keyphrases
- juvenile idiopathic arthritis
- ankylosing spondylitis
- healthcare
- end stage renal disease
- palliative care
- ejection fraction
- newly diagnosed
- small molecule
- systemic lupus erythematosus
- stem cells
- combination therapy
- quality improvement
- hiv infected
- disease activity
- risk assessment
- smoking cessation
- patient reported
- optical coherence tomography